Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Avellino Lab USA has announced additional production shifts to scale up the manufacturing of the SARS-CoV-2/COVID-19 Test (AvellinoCoV2), its newly developed coronavirus (Covid-19) diagnostic.
This ultra-rapid genetic test helps clinicians diagnose Covid-19 caused by a SARS-CoV-2 virus infection by identifying and isolating the genetic markers as approved by the FDA and the CDC.
The test is considered to be in high demand among health systems, public health services and first-responders due its precision, speed and ability to detect the disease in asymptomatic patients.
To ramp up the production of AvellinoCoV2 test, company is expanding its operations into the genetic diagnostics lab as used for its AvaGen test that assesses the risk of developing keratoconus and the presence of corneal dystrophies.
In addition, the company is temporarily suspending sequencing operations of its AvaGen genetic to meet the demand for its Covid-19-test.
Avellino Group chairman Gene Lee said: “We appreciate the support from eye care professionals who are now using the AvaGen genetic test to care for their corneal patients. We understand the breakthrough importance of the AvaGen test in treating patients with complex corneal conditions.
“Avellino will restart production of the AvaGen genetic test as soon as we have fulfilled our public health obligation surrounding the coronavirus pandemic.”
The validation process for AvellinoCoV2 was completed by the company earlier this month, according to the FDA issued guidance for laboratories developing Covid-19 tests.